REGISTRATION
RIGHTS AGREEMENT


 


This
Registration Rights Agreement (“Agreement”) is entered into as of August 13, 2019 by and between AgeX
Therapeutics, Inc., a California corporation (the “Company”) and the Juvenescence Limited, a company incorporated
in the British Virgin Islands (“Holder”).


 


NOW,
THEREFORE, the parties agree as follows:


 


1.
Certain Definitions. As used in this Agreement the following terms shall have the following respective meanings:


 


(a)
“Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute and the rules and regulations
of the Commission thereunder, all as the same shall be in effect at the time.


 


(b)
“Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering
the Act.


 


(c)
“Holder” shall mean Juvenescence Limited, a company incorporated in the British Virgin Islands, and its transferees
as permitted by Section 6.


 


(d)
The terms “register,” “registered” and “registration” refer to a registration
effected by preparing and filing a registration statement in compliance with the Act, and the declaration or ordering of the effectiveness
of such registration statement.


 


(e)
“Loan Agreement” means the Loan Facility Agreement between the Company and Holder, dated August 13,
2019, pursuant to which the Company agreed to issue the Shares and the Warrants.


 


(f)
“Registrable Securities” means the Shares, Warrants, and Warrant Shares. Any securities that are (i) distributed
as a dividend or otherwise with respect to Registrable Securities, (ii) issuable upon the exercise or conversion of Registrable
Securities, or (iii) issued or issuable in exchange for or through conversion of Registrable Securities pursuant to a recapitalization,
reorganization, merger, consolidation or other transaction shall also constitute Registrable Securities.


 


(g)
“Shares” means 19,000 shares of common stock, par value $0.0001 per share, of the Company issued by the Company
upon the Company’s first draw down from the credit line under the Loan Agreement.


 


(h)
“Warrants” means up to 150,000 common stock purchase warrants governed by that certain Warrant Agreement, dated
August 13, 2019.


 


(i)
“Warrant Shares” means shares of common stock, par value $0.0001 per share, of the Company issuable by the
Company pursuant to the exercise of Warrants.


 





    
    	1

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    


 


2.
Registration Rights.


 


(a)
Filing of Registration Statement with Respect to Shares and Warrant Shares. The Company agrees, at its expense, to file
a registration statement with the Commission to register Registrable Securities under the Act, and to take such other actions
as may be necessary to allow the Registrable Securities to be freely tradable, without restrictions under the Act, provided that
the Company is eligible to register such Registrable Securities on Form S-3. Such registration statement shall be filed following
a written request for registration from the Holder. The Company will use commercially reasonable efforts to cause the registration
statement to become effective as promptly as practicable after filing. The Company will make all filings required under applicable
state securities or “blue sky” laws so that the Registrable Securities being registered shall be registered or qualified
for sale under the securities or blue sky laws of New York, California and such jurisdictions as shall be reasonably appropriate
for distribution of the Shares and Warrant Shares covered by the registration statement. The registration statement shall be a
“shelf” registration pursuant to Rule 415 (or similar rule that may be adopted by the Commission) and shall provide
that the Holder’s plan of distribution is to offer and sell Shares or Warrant Shares from time to time at market prices
or prices related to market prices; provided, that a registration statement may be amended to provide for an underwritten public
offering of Registrable Securities included in the registration statement (excluding Warrants except as provided in Section 2(e))
if the Holder submits to the Company a written notice to such effect with a copy of the applicable underwriting documents and
such other relevant information concerning the offering as the Company may request. The Company shall use commercially reasonable
efforts to keep each such registration statement effective until the earlier of (i) completion of the distribution or distributions
being made pursuant thereto, and (ii) such time as the Holder is eligible to sell its Shares and Warrant Shares under Rule 144
under the Act without application of the manner of sale and volume limitations under Rule 144. The Company will furnish to the
Holder such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the
Act and such other related documents as the Holder may reasonably request in order to effect the sale of its Registrable Securities.


 


(b)
“Piggy-Back Registration” of Shares. If, at any time the Company proposes to register any of its securities
under the Act (otherwise than pursuant to (i) this Agreement, (ii) a registration statement pertaining to subscription rights
distributed to Company shareholders, and (iii) a registration on a Form S-8 or any other form if such form cannot be used for
registration of the Registrable Securities pursuant to its terms), and the Shares and Warrant Shares shall not then be eligible
for sale by the Holder under Rule 144 under the Act, the Company shall, as promptly as practicable, give written notice to the
Holder. The Company shall include in such registration statement the Registrable Securities proposed to be sold by the Holder,
subject to the provisions of Section 2(e) if the offering is made through underwriters. If the registration by the Company pertains
to an offering by the Company without underwriters, Holder shall not be entitled to participate as a party to any stock sale or
purchase agreement entered into by the Company for the sale of securities for its own account or to otherwise sell Registrable
Securities to any prospective purchaser to whom the Company offers registered securities for the Company’s account other
than in “at-the-market” transactions as defined in Rule 415 promulgated under the Act.


 




    	2

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    

 


(c)
Costs of Registration. The Company shall pay the cost of the registration statements filed pursuant to this Agreement,
including without limitation all registration and filing fees, fees and expenses of compliance with securities or blue sky laws
(including counsel’s fees and expenses in connection therewith), printing expenses, messenger and delivery expenses, internal
expenses of the Company, listing fees and expenses, and fees and expenses of the Company’s counsel, independent accountants
and other persons retained or employed by the Company. Holder shall pay any underwriters discounts applicable to the Registrable
Securities.


 


(d)
Other Securities. Any registration statement filed pursuant to this Agreement may include other securities of the Company
which are held by other persons who, by virtue of agreements with the Company or permission given, are entitled to include their
securities in such registration.


 


(e)
Underwriting. If Holder wishes to include Shares, Warrant Shares, or other Registrable Securities (but not Warrants) in
a registration under Section 2(b), or if Holder intends to distribute Shares by means of an underwriting to be registered under
Section 2(a), Holder shall so advise the Company prior to the effective date of the registration statement filed by the Company.
Holder shall not have the right to include Warrants in an underwriting unless either (i) the inclusion of such Warrants in the
registration is for the purpose of permitting the underwriters to exercise the Warrants and sell the Registrable Securities issued
upon such exercise, or (ii) the Company expressly consents in writing to such inclusion in its sole discretion.


 


The
Company shall enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting
the Holder, in the case of a registration under Section 2(a), or selected by the Company in its sole discretion in the case of
a registration under Section 2(b). Notwithstanding any other provision of this Agreement, if the managing underwriter advises
the Holder and the Company in writing that marketing factors require a limitation of the number of shares to be underwritten,
then, the number of Registrable Securities that may be included in the registration and underwriting shall be allocated first
to the Company in a registration under Section 2(b), and then, in a registration under Section 2(a) or Section 2(b), among Holder
and any other holders of securities having rights to include their securities in the registration, at the time of filing the registration
statement. No Registrable Securities excluded from the underwriting by reason of the managing underwriter’s marketing limitation
shall be included in such registration.


 




    	3

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    

 


If
Holder or any other holder of securities eligible for inclusion in the registration disapproves of the terms of the underwriting,
such person may elect to withdraw from the underwriting and registration by written notice to the Company and the managing underwriter.
The Registrable Securities and/or other securities so withdrawn shall also be withdrawn from the registration; provided, however,
that, if by the withdrawal of such Registrable Securities or other securities a greater number of Registrable Securities held
by other securities held by persons having rights to participate in such registration may be included in such registration (up
to the maximum of any limitation imposed by the underwriters), then the Company shall offer to Holder and other persons who have
included Registrable Securities or other securities in the registration the right to include additional Registrable Securities
(excluding Warrants except as permitted in Section 2(e)) or other securities in the same proportion used in determining the underwriter
limitation.


 


(f)
Waiver. Notwithstanding any other provision of this Agreement, the rights of the Holder under Section 2(b) may be waived
by the Holder.


 


(g)
Limitation on Company Liability. The Company shall have no obligation to make any cash settlement or payment to Holder,
or to issue any additional Registrable Securities or other securities to Holder, in the event that the Company is unable to effect
or maintain in effect the registration of any Registrable Securities under the Act or any state securities law despite the Company’s
commercially reasonable efforts so to do.


 


3.
Indemnification.


 


(a)
The Company will indemnify, defend and hold harmless Holder, each of its officers, directors and partners, and each person who
controls Holder within the meaning of the Act, and each underwriter, if any, and each person who controls any underwriter within
the meaning of the Act from and against all expenses, claims, losses, damages and liabilities (or actions commenced or threatened
in respect thereof), including any of the foregoing incurred in settlement of any litigation commenced or threatened (other than
a settlement effected without the consent of the Company, which consent will not unreasonably be withheld), to the extent such
expenses, claims, losses, damages and liabilities (or actions commenced or threatened in respect thereof) arise out of or are
based on (i) any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement or
prospectus, or any amendment or supplement thereto, offering Registrable Securities, or any omission to state therein a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were
made, not misleading, or (ii) any violation, by the Company, of any rule or regulation promulgated under the Act and applicable
to the Company and relating to any registration of Registrable Securities by the Company under the Act. The Company will reimburse
Holder, each of its officers, directors and partners, and each person controlling Holder, each such underwriter and each such
person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating
or defending any such claim, loss, damage, liability or action; provided that the Company will not be liable in any such case
to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission
based upon written information furnished to the Company by Holder or underwriter or controlling person specifically for use in
connection with the registration or offering of Registrable Securities.


 




    	4

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    

 


(b)
Holder will, if Registrable Securities held by Holder are included in a registration under the Act or under any state securities
law, indemnify, defend and hold harmless the Company, each of its directors and officers, and each independent accountant of the
Company, each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who
controls the Company or such underwriter within the meaning of the Act, from and against all claims, losses, damages and liabilities
(or actions commenced or threatened in respect thereof) arising out of or based on (i) any untrue statement (or alleged untrue
statement) of a material fact contained in any such registration statement or prospectus, or any amendment or supplement offering
Registrable Securities, or any omission (or alleged omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or (ii) any violation,
by Holder, of any rule or regulation promulgated under the Act applicable to Holder and relating to action or inaction required
of Holder in connection with any registration of Registrable Securities. Holder will reimburse the Company and its directors,
officers, partners, persons, accounting firms, underwriters, or control persons for any legal or any other expenses reasonably
incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in each case to the
extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is
made in such registration statement or prospectus in reliance upon and in conformity with written information furnished to the
Company or any underwriter by Holder specifically for use therein; provided, however, that the obligations of Holder under this
Section 3(b) shall be limited to an amount equal to the net proceeds to Holder from the sale of Registrable Securities pursuant
to such registration.


 


(c)
Each party entitled to indemnification under this Section 3 (the “Indemnified Party”) shall give notice to
the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense
of any such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the
defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall
not unreasonably be withheld). The Indemnified Party may participate in such defense at the Indemnified Party’s own expense.
The failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations
under this Section 3 except to the extent such failure is prejudicial to the ability of the Indemnifying Party to defend such
action, but such failure shall not relieve the Indemnifying Party of any liability that the Indemnifying Party may have to any
Indemnified Party otherwise than under this Section 3. No Indemnifying Party, in the defense of any such claim or litigation,
shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which
does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release
from all liability in respect to such claim or litigation.


 




    	5

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    

 


4.
Information by Holder. Holder shall furnish to the Company and to each underwriter, upon the Company’s request, such
information regarding Holder and the distribution proposed by Holder as shall be required in connection with any registration
of Registrable Securities.


 


5.
Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which
may permit the sale of the Registrable Securities to the public without registration, the Company agrees to:


 


(a)
Use commercially reasonable efforts to file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) at such times as the
Company is subject to the reporting requirements under Section 13 of the Exchange Act; and,


 


(b)
So long as Holder owns any Registrable Securities, furnish to Holder forthwith upon written request a written statement by the
Company as to its compliance with the reporting requirements of the Exchange Act, a copy of the most recent annual or quarterly
report of the Company, and such other reports and documents so filed by the Company under the Exchange Act as Holder may reasonably
request in availing itself of any rule or regulation of the Commission allowing Holder to sell any such securities without registration.


 


6.
Transfer of Registration Rights. The rights to cause the Company to register securities under this Agreement may be assigned:
(a) to an “affiliate” (defined as an entity that controls, is controlled by, or under common control with the transferor);
(b) to one or more of its general partners, limited partners, or members if the transferor is a partnership or limited liability
company; or (c) to any other transferee or assignee of an aggregate of twenty-five percent (25%) or more of the transferor’s
Registrable Securities; provided, that as a condition to any transfer of such rights the transferor must give the Company written
notice at the time or within a reasonable time after said transfer, stating its desire to transfer such rights, the name and address
of the transferee or assignee, and identifying the securities with respect to which such registration rights are being assigned;
provided, further, that nothing in this Section shall be construed in any way to limit any restriction or condition on transfer
of any Registrable Securities imposed by any other agreement between Holder and the Company, the Act, any rule or regulation promulgated
under the Act, or any state securities or blue sky law or any rule or regulation thereunder. In the event of any such transfer,
the transferee shall have the rights and obligations of Holder, provided that the rights under Section 2(a) may be exercised only
by holders of not less than 50% of the Registrable Securities.


 




    	6

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    

 


7.
Computation of Certain Percentages. Where any provision of this Agreement provides for the exercise, waiver, or amendment
of any rights upon the action of a holder of a specified percentage of Registrable Securities, such percentage shall be determined
based upon the aggregate number of Registrable Securities issued and outstanding, and any holders of Warrants shall be deemed
to own the Registrable Securities issuable upon the exercise of such Warrants.


 


8.
Miscellaneous.


 


(a)
Governing Law. This Agreement shall be governed in all respects by the laws of the State of California, as applied to contracts
entered into in California between California residents and to be performed entirely within California.


 


(b)
Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit
of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.


 


(c)
Entire Agreement; Amendment. This Agreement constitutes the full and entire understanding and agreement between the parties
with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended, waived, discharged or terminated
orally, but only by a written instrument signed by the Company and Holder.


 


(d)
Notices, etc. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed
by first-class mail, postage prepaid, or otherwise delivered by hand, by messenger or next business day air freight services,
addressed (i) if to Holder at Holder’s address set forth on the signature page hereto, or at such other address as Holder
shall have furnished to the Company in writing, or (ii) if to the Company, at 1010 Atlantic Avenue, Suite 102, Alameda, California
94501; attention: Chief Financial Officer, or at such other address as the Company shall have furnished to Holder in writing.


 


(e)
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party, upon any breach
or default of any other party under this Agreement, shall impair any such right, power or remedy, nor shall it be construed to
be a waiver of or acquiescence in any such breach or default or any similar breach or default thereafter occurring. A waiver of
any single breach or default shall not be deemed a waiver of any other breach or default theretofore or thereafter occurring.
Any waiver, permit, consent or approval of any kind or character of any breach or default under this Agreement, or any waiver
of any provisions or conditions of this Agreement, must be made in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement, or by law or otherwise afforded to any party, shall be cumulative
and not alternative.


 


(f)
Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality
and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.


 


(g)
Titles and Subtitles. The titles of the sections and subparagraphs of this Agreement are for convenience of reference only
and are not to be considered in construing this Agreement.


 


(h)
Counterparts. This Agreement may be executed in any number of counterparts (including by separate counterpart signature
pages), each of which shall be an original, but all of which together shall constitute one instrument. Any counterpart of this
Agreement may be signed by electronic or facsimile, and such electronic or facsimile signature shall be deemed an original signature.


 


[Signature
page follows.]


 




    	7

AgeX Therapeutics, Inc.
Registration Rights Agreement


    	 



    

 


IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 


COMPANY:


 


	AGEX
    THERAPEUTICS, INC.	 
	 	 
	By:	/s/
    Russell L. Skibsted	 
	 	Russell
    L. Skibsted,	 
	 	Chief
    Financial Officer	 
	 	 	 
	By:	/s/ Judith Segall 	 
	 	Judith
    Segall, Secretary	 


 


HOLDER:


 


	JUVENESCENCE LIMITED	 
	 	 
	By:  	/s/
    Gregory Bailey	 
	 	 	 
	Name:	Gregory
    Bailey	 
	 	 	 
	Title:	Authorized Signatory	 



 


	Address
    for Notice:	4th
Floor Viking House	 
	 	 	 
	 	Nelson Street	 
	 	 	 
	 	Isle of Man IMI2AH	 


 




    	8

AgeX Therapeutics, Inc.
Registration Rights Agreement